Professional Documents
Culture Documents
Textbook Attention Deficit Hyperactivity Disorder Adult Outcome and Its Predictors 1St Edition Hechtman Ebook All Chapter PDF
Textbook Attention Deficit Hyperactivity Disorder Adult Outcome and Its Predictors 1St Edition Hechtman Ebook All Chapter PDF
https://textbookfull.com/product/fetal-and-early-postnatal-
programming-and-its-influence-on-adult-health-1st-edition-
nielsen/
https://textbookfull.com/product/organization-design-and-its-
impact-on-the-digital-innovation-process-and-the-digital-
innovation-outcome-robert-eirich/
https://textbookfull.com/product/from-human-attention-to-
computational-attention-a-multidisciplinary-approach-1st-edition-
matei-mancas/
https://textbookfull.com/product/coulson-and-richardsons-
chemical-engineering-fourth-edition-volume-3a-chemical-and-
biochemical-reactors-and-reaction-engineering-r-ravi/
Attention Pays: How to Drive Profitability,
Productivity, and Accountability 1st Edition Neen James
https://textbookfull.com/product/attention-pays-how-to-drive-
profitability-productivity-and-accountability-1st-edition-neen-
james/
https://textbookfull.com/product/endodontic-prognosis-clinical-
guide-for-optimal-treatment-outcome-1st-edition-nadia-chugal/
https://textbookfull.com/product/artificial-intelligence-for-
bone-disorder-diagnosis-and-treatment-1st-edition-malviya/
https://textbookfull.com/product/structuring-mind-the-nature-of-
attention-and-how-it-shapes-consciousness-1st-edition-sebastian-
watzl/
https://textbookfull.com/product/interpersonal-psychotherapy-for-
posttraumatic-stress-disorder-1st-edition-markowitz/
i
Attention Deficit
Hyperactivity Disorder
E D I T E D B Y L I LY H E C H T M A N , M D , F R C P,
ABPN
PR OFE SSOR OF PSYC H IAT RY AN D PEDIAT RIC S
DIREC T OR OF RESEARC H
D I V I SI ON OF C H IL D PSYC H IAT RY
M CGI LL UNI VERSIT Y H EALT H C EN T RE
M ONTR E A L C H IL DREN ’S H OSPITAL
1
iv
1
Oxford University Press is a department of the University of Oxford. It furthers
the University’s objective of excellence in research, scholarship, and education
by publishing worldwide. Oxford is a registered trade mark of Oxford University
Press in the UK and certain other countries.
This material is not intended to be, and should not be considered, a substitute for medical or other
professional advice. Treatment for the conditions described in this material is highly dependent on
the individual circumstances. And, while this material is designed to offer accurate information with
respect to the subject matter covered and to be current as of the time it was written, research and
knowledge about medical and health issues is constantly evolving and dose schedules for medications
are being revised continually, with new side effects recognized and accounted for regularly. Readers
must therefore always check the product information and clinical procedures with the most up-to-date
published product information and data sheets provided by the manufacturers and the most recent
codes of conduct and safety regulation. The publisher and the authors make no representations or
warranties to readers, express or implied, as to the accuracy or completeness of this material. Without
limiting the foregoing, the publisher and the authors make no representations or warranties as to the
accuracy or efficacy of the drug dosages mentioned in the material. The authors and the publisher do
not accept, and expressly disclaim, any responsibility for any liability, loss or risk that may be claimed
or incurred as a consequence of the use and/or application of any of the contents of this material.
9 8 7 6 5 4 3 2 1
Printed by WebCom, Inc., Canada
v
I would like to dedicate this book to my inspiring mentor Dr. Gabrielle Weiss
who started me on this exciting journey, my wonderful supportive colleagues
who contributed chapters and with whom it is a pleasure to work, and our
patients who share their courageous struggles and teach us so much.
Finally, this book and much of my career would not be possible without the
encouragement, humour, and support of my husband Peter, who usually
sees the glass as half-full.
vi
vii
CONTENTS
CONTRIBUTORS ix
1. Introduction 1
Lily Hechtman
viii Contents
INDEX 291
ix
CONTRIBUTORS
x Contributors
18
16.9
16
14.8
14
12
10 nonADHD
8 ADHD
4
2.1 1.8
2 1.6
0.3
0
Times drank 5+ drinks Times drunk AUD symptom score
Figure 5.1
26
From Molina and Pelham From Rhodes et al. (in press);
(2003); M age 15 M age 18
24
22 21.58
non-ADHD
20 ADHD 19.55
18 17.39
16.99
16.32
15.91
16 15.33
13.9
14
12
M age first tried a M age first daily M age first tried a M age first daily
cigarette smoking cigarette smoking
Figure 5.2
2
Figure 5.3
3
Figure 5.4
100
Syndromatic
78% Remission
80
65% 13% Functional
60 8% Persistence
Medicated
%
22%
40 Symptomatic
Persistence
20 35%
Syndromatic
Persistence
0
Syndromatic Persistence
Remission
Figure 6.1
4
(A) 70
Interval Lifetime
*
60
* p < 0.05 Lifetime
p < 0.05 Interval
50 *
40 *
%
*
30 *
*
20
*
10
0
Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD
MOOD Major Bipolar ANXIETY Agoraphobia Social Obsessive- Specific Panic Generalized
DISORDERS depressive disorder DISORDERS phobia compulsive phobia disorder anxiety
disorder disorder disorder
Figure 6.2a
5
(B) 90
80 Interval Lifetime
70
p < 0.05 Lifetime
60
* p < 0.05 Interval
50
%
40
30
* *
20 *
10
0
Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD Controls ADHD
40
ADHD Baseline
ADHD Follow-up
30
Control Follow-up
20
%
10
p < 0.05 vs. p < 0.05 vs.
ADHD females ADHD males
0
Control Females Control Males ADHD Females ADHD Males
Figure 6.3
–1
–2
7.5 11 14 17.5 21
Age in years
Figure 6.4
7
52%
“C” average or lower*
27%
37%
Had a tutor*
13%
37%
Had special classes*
10%
ADHD (N = 464)
*p ≤ .001
52%
Currently employed*
72%
34%
Employed full-time*
57%
48%
Not currently employed*
27%
ADHD (N = 500)
14%
Looking for work*
5% Non-ADHD (N = 501)
*p ≤ .001
Figure 6.5ab
8
C. Overall SES
3
z = 3.47
(higher score = lower SES)
Hollingshead mean score
p = 0.001
2.5
2.5
2
1.9
1.5
B. College graduate
100
80 84.6 z = –4.78
p < 0.001
60
Percent
40
37.9
20
z = –3.12
6.5 6.6 p = 0.002
z = –5.36
6
6.1 p < 0.001
5.5
5 5.2
5.1
4.5
4
Educational level (1 to 7) Occupational level (1 to 9)
Controls ADHD
Figure 6.5c
9
Figure 6.6
10
Major Depression Multiple Anxiety
(A) 1.00 1.00
No Stimulant Therapy Lifetime Stimulant Therapy No Stimulant Therapy Lifetime Stimulant Therapy
0.75 0.75
Failure function
Failure function
2 χ2(1) = 17.8, p < 0.001
χ (1) = 19.7, p < 0.001
0.50 0.50
0.25 0.25
0.00 0.00
0 5 10 15 20 25 30 0 5 10 15 20 25 30
Age at Onset Age at Onset
Bipolar Disorder
1.00
No Stimulant Therapy Lifetime Stimulant Therapy
0.75
Failure function
0.25
0.00
0 5 10 15 20 25 30
Age at Onset
Figure 6.7a
11
ASPD Conduct Disorder
(B) 1.00 1.00
No Stimulant Therapy Lifetime Stimulant Therapy No Stimulant Therapy Lifetime Stimulant Therapy
0.75 0.75
Failure function
Failure function
χ2(1) = 1.3, p = 0.258 χ2(1) = 21.4, p < 0.001
0.50 0.50
0.25 0.25
0.00 0.00
0 5 10 15 20 25 30 0 5 10 15 20 25 30
Age at Onset Age at Onset
Oppositional Defiant Disorder
1.00
No Stimulant Therapy Lifetime Stimulant Therapy
0.75
Failure function
0.25
0.00
0 5 10 15 20 25 30
Age at Onset
Figure 6.7b
12
(C) Repeated Grade (D)
1.00 100 Stimulant
*p < 0.05 vs. Controls Therapy* No Stimulant
Therapy*
0.75 75
Failure function
%
0.25 25 Controls
0.00
0 5 10 15 20 25 30 0 10 20 30
Age at Onset Age
No Stimulant Therapy Lifetime Stimulant Therapy
Figure 6.7cd
13
20
15
10
5
0
Controls ADHD
50
z = 2 .49, p = 0.01
40
30
%
20
10
0
ADHD ADHD+DESR
(B) 25%
20%
18.0%
15%
p < 0.001
10%
5%
1.0%
0%
ADHD Probands Control Probands
Figure 6.8
14
Seed Region (A) Control (N = 17) (B) Control > Persistent ADHD
t=
2.2 5.0 MPFC
Figure 6.9
25
with a bachelor’s degree
Percentage individuals
public assistance
30 20
15
20
10
10
5
0 0
LNCG MTA Persistent Remittent LNCG MTA Persistent Remittent
ADHD ADHD ADHD ADHD
15
partners
10
0
LNCG MTA Persistent Remittent
ADHD ADHD
Figure 8.2
15
12 14
with depression *
10 12
8 10
8
6
6
4
4
2 2
0 0
LNCG MTA Persistent Remittent LNCG MTA Persistent Remittent
ADHD ADHD ADHD ADHD
Figure 8.3
B(SE) = .58 (.26) B(SE) = .06 B(SE) = .07 B(SE) = .03 (.24)
p = .028** (.29) p = .84 (.21) p = .73 p = .88
18
14
with alcohol use problems
16
reporting any police contact
Percentage individuals
Percentage individuals
12 14
10 12
8 10
8
6
6
4
4
2 2
0 0
LNCG MTA Persistent Remittent LNCG MTA Persistent Remittent
ADHD ADHD ADHD ADHD
Figure 8.4
16
1
Introduction
L I LY H E C H T M A N
A
good deal of interest and controversy currently exist regarding the
high rate of diagnosis of Attention Deficit Hyperactivity Disorder
(ADHD). Some reports by specialists in the field and in the media
have suggested that ADHD is overdiagnosed and thus overtreated. This
sentiment is particularly true for ADHD in adulthood. In fact, there is
some skepticism regarding the existence of ADHD in adults, given that
early on it was believed that children outgrew this condition as the hyper-
activity and impulsivity tended to decrease with age.
However, well-controlled prospective follow-up studies (which will be
reviewed in this book) first showed that symptoms of ADHD, particu-
larly symptoms of inattention, continued into adulthood and caused sig-
nificant functional and clinical impairment, thus laying the groundwork
for the diagnosis of ADHD in adulthood. These prospective follow-up
studies have appeared in the literature intermittently over the last 20 to
30 years and, therefore, did not have the impact they deserved in help-
ing establish the validity of the diagnosis in adulthood. No other publi-
cation to date brings together in one place these various well-controlled
2
prospective follow-up studies, which show that more than half of the chil-
dren with ADHD continue to have significant symptoms and impairment
in adulthood.
This book thus addresses an important controversy—namely the
validity of an ADHD diagnosis in adults, which is of great interest
currently. The fifth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) has contributed to the support of this diag-
nosis, not only by providing an Adult ADHD diagnostic category but
also recognizing that the symptom criteria requiring six out of nine
symptoms in either the Inattentive or Hyperactive–Impulsive symptom
category was not appropriate for adults because it required adults to
score above the 99th percentile whereas most conditions require scores
above the 93rd percentile. DSM-5 thus lowered the symptom criteria
to five out of nine symptoms for anyone over the age of 17 years. This
modification in symptom criteria for adults clearly recognized the pres-
ence of ADHD in adulthood and does much to validate the diagnosis
in this age group.
These studies also show, however, that not all children with ADHD go
on to have the symptoms and impairment in adulthood. Professionals;
researchers; pediatricians; child, adolescent, and adult psychiatrists; fam-
ily physicians; psychologists; social workers; and teachers frequently are
asked about the prognosis of this condition. Will the child always be
impaired? Will he grow up to be a delinquent or addict? Will he be able
to complete school? Go on to university? These studies provide a compre-
hensive view of the prognosis of this condition—a view that professionals
cannot obtain elsewhere.
Finally, what factors may influence long-term outcome and progno-
sis? Identifying such prognostic factors is critical because this has current
treatment implications if more positive outcomes are sought. Again, pro-
fessionals (outlined above) will be able to access these relevant factors in
one place and use them in their treatment planning.
At this point in time no other book brings all these diverse studies
together and provides a sound basis for the diagnosis of ADHD in adult-
hood. These chapters offer a clear view of possible outcomes and progno-
sis, which professionals require to address patient concerns adequately,
Another random document with
no related content on Scribd:
1.E.5. Do not copy, display, perform, distribute or redistribute
this electronic work, or any part of this electronic work, without
prominently displaying the sentence set forth in paragraph 1.E.1
with active links or immediate access to the full terms of the
Project Gutenberg™ License.
1.E.6. You may convert to and distribute this work in any binary,
compressed, marked up, nonproprietary or proprietary form,
including any word processing or hypertext form. However, if
you provide access to or distribute copies of a Project
Gutenberg™ work in a format other than “Plain Vanilla ASCII” or
other format used in the official version posted on the official
Project Gutenberg™ website (www.gutenberg.org), you must, at
no additional cost, fee or expense to the user, provide a copy, a
means of exporting a copy, or a means of obtaining a copy upon
request, of the work in its original “Plain Vanilla ASCII” or other
form. Any alternate format must include the full Project
Gutenberg™ License as specified in paragraph 1.E.1.
• You pay a royalty fee of 20% of the gross profits you derive from
the use of Project Gutenberg™ works calculated using the
method you already use to calculate your applicable taxes. The
fee is owed to the owner of the Project Gutenberg™ trademark,
but he has agreed to donate royalties under this paragraph to
the Project Gutenberg Literary Archive Foundation. Royalty
payments must be paid within 60 days following each date on
which you prepare (or are legally required to prepare) your
periodic tax returns. Royalty payments should be clearly marked
as such and sent to the Project Gutenberg Literary Archive
Foundation at the address specified in Section 4, “Information
about donations to the Project Gutenberg Literary Archive
Foundation.”
• You comply with all other terms of this agreement for free
distribution of Project Gutenberg™ works.
1.F.
Most people start at our website which has the main PG search
facility: www.gutenberg.org.